Triple Negative Breast Cancer Global Market Report 2025

The triple negative breast cancer market size has grown strongly in recent years. It will grow from $0.72 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to the rising number of women, increasing demand for TNBC treatments, greater awareness of early breast cancer detection, a growing patient population, and increased healthcare spending.

The triple negative breast cancer market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to the rising cases of breast cancer, the growing incidence of triple-negative breast cancer, expanding healthcare infrastructure, increasing research and development activities, and the rising cases of HER2-positive breast cancer. Key trends during this period include innovative TNBC treatments, advancements in radiation techniques, improvements in diagnostic technology, increasing demand for personalized medicine, and ongoing product innovation.

The advancement of healthcare facilities is expected to drive the growth of the triple-negative breast cancer (TNBC) market. Healthcare facilities, including hospitals, clinics, and diagnostic centers, provide medical care and services to patients. Improvements in healthcare infrastructure result from increased investment, a focus on patient-centered care, population growth, and aging demographics. Enhanced healthcare facilities support TNBC treatment by offering access to advanced diagnostic technologies, personalized therapies, multidisciplinary care teams, and improved patient education, leading to better early detection, treatment outcomes, and survival rates. For example, in May 2023, the American Health Care Association reported that the number of hospitals in the United States increased by 0.591%, from 6,093 in the previous year to 6,129. As a result, the improvement of healthcare facilities is fueling the growth of the TNBC market.

Leading companies in the TNBC market are focused on developing innovative treatments, such as small molecule drugs, to improve the specificity and effectiveness of cancer therapies. Small molecule drugs are low molecular weight compounds capable of penetrating cells to modulate biological processes, making them effective against cancer and other diseases. For instance, in December 2024, Lantern Pharma Inc., a US-based clinical-stage biotechnology company, announced the investigational drug candidate LP-184 for TNBC treatment. The U.S. Food and Drug Administration (FDA) granted Fast Track designation for LP-184, a next-generation acylfulvene and small molecule drug designed to selectively damage DNA in cancer cells with specific biomarkers or mutations in DNA damage repair pathways. Lantern’s proprietary RADR AI platform helps identify patient populations and cancer subtypes likely to respond to the treatment. LP-184 is currently being evaluated across multiple solid tumors and has demonstrated nanomolar potency, showing promise in drug-resistant cancers and advancing targeted cancer therapy.

In December 2024, Galera Therapeutics Inc., a US-based biopharmaceutical company, acquired Nova Pharmaceuticals Inc. to advance its clinical development efforts. This acquisition enables Galera to further explore its inhibitor’s potential in treating TNBC. Nova Pharmaceuticals Inc. is a US-based clinical-stage biotechnology company specializing in developing novel treatments for triple-negative and metaplastic breast cancer.

Major players in the triple negative breast cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Novartis AG, Fresenius Kabi AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Illumina Inc., Bio-Rad Laboratories Inc., Seagen Inc., MacroGenics Inc., Immutep Limited, G1 Therapeutics Inc., Galera Therapeutics Inc., HiberCell Inc., Infinity Pharmaceuticals Inc.

North America was the largest region in the triple negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in triple-negative breast cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the triple-negative breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Triple-negative breast cancer (TNBC) is an aggressive and rapidly growing subtype of breast cancer that lacks estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2), making it unresponsive to hormonal therapies or HER2-targeted treatments. Compared to other breast cancer types, TNBC is more challenging to treat and has a higher recurrence rate. It is more prevalent in younger women, African American women, and individuals with BRCA1 mutations, highlighting its genetic predisposition.

The primary treatment options for TNBC include chemotherapy, immunotherapy, targeted therapy, surgery, radiation therapy, and other approaches. Chemotherapy works by using drugs to destroy cancer cells or inhibit their growth. Diagnosis involves various tests, such as imaging techniques, assays, and breast biopsies. These treatments and diagnostic methods are utilized by hospitals, specialty clinics, ambulatory surgical centers, and other healthcare facilities.

The triple-negative breast cancer market research report is one of a series of new reports that provides triple-negative breast cancer market statistics, including triple-negative breast cancer industry global market size, regional shares, competitors with a triple-negative breast cancer market share, detailed triple-negative breast cancer market segments, market trends and opportunities, and any further data you may need to thrive in the triple-negative breast cancer industry. This triple-negative breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The triple-negative breast cancer market consists of revenues earned by entities by providing services such as diagnostic testing, biomarker analysis, drug development and genetic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The triple-negative breast cancer market also includes sales of genetic testing kits, companion diagnostic tests, radiopharmaceuticals and clinical trial drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.